KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Enterprise Value (2016 - 2025)

Arbutus Biopharma's Enterprise Value history spans 16 years, with the latest figure at -$93.7 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 26.68% year-over-year to -$93.7 million; the TTM value through Sep 2025 reached -$93.7 million, up 26.68%, while the annual FY2024 figure was -$122.6 million, 2.68% up from the prior year.
  • Enterprise Value for Q3 2025 was -$93.7 million at Arbutus Biopharma, up from -$98.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$78.4 million in Q2 2021 and bottomed at -$155.3 million in Q4 2021.
  • The 5-year median for Enterprise Value is -$124.3 million (2023), against an average of -$119.5 million.
  • The largest annual shift saw Enterprise Value tumbled 399.55% in 2021 before it surged 38.37% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$155.3 million in 2021, then rose by 5.41% to -$146.9 million in 2022, then increased by 14.23% to -$126.0 million in 2023, then grew by 2.68% to -$122.6 million in 2024, then rose by 23.59% to -$93.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Enterprise Value are -$93.7 million (Q3 2025), -$98.1 million (Q2 2025), and -$102.0 million (Q1 2025).